Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-06T15:15:08.170Z Has data issue: false hasContentIssue false

Challenges in the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy in the young

Published online by Cambridge University Press:  06 July 2021

Hirokuni Yamazawa*
Affiliation:
Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
Atsuhito Takeda
Affiliation:
Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
Gaku Izumi
Affiliation:
Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan
*
Author for correspondence: Hirokuni Yamazawa, MD, PhD, Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, North 15 West 7, Kitaku Sapporo, Hokkaido 060-8638 Japan. Tel: 81 11 706 5954; Fax: 81 11 706 7898. E-mail: yamazawa@med.hokudai.ac.jp

Abstract

A case of hypertrophic cardiomyopathy in the transition from childhood to adulthood, which was low risk by the conventional risk assessment model, medium risk by the adult risk prediction model, and high risk by the paediatric risk prediction model, was inserted an implantable cardioverter-defibrillator. Three years post-implantation, the patient was resuscitated with an appropriate discharge of cardioverter-defibrillator.

Type
Brief Report
Copyright
© The Author(s), 2021. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gersh, BJ, Maron, BJ, Bonow, RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e212e260.CrossRefGoogle Scholar
O’Mahony, C, Jichi, F, Pavlou, M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35: 20102020.CrossRefGoogle Scholar
Yamazawa, H, Takeda, A, Takei, K, Furukawa, T. Primary prevention of sudden cardiac death in a low-risk child with familial hypertrophic cardiomyopathy: the role of cardiac magnetic resonance imaging. Clin Res Cardiol 2014; 103: 7577.10.1007/s00392-013-0631-9CrossRefGoogle Scholar
Sridharan, A, Maron, BJ, Madias, C, et al. Abstract 12090: modern treatments can abolish mortality in pediatric patients with hypertrophic cardiomyopathy. Circulation 2019; 140: A12090.Google Scholar
Nakagawa, S, Okada, A, Nishimura, K, et al. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy. Am J Cardiol 2018; 122: 19391946.10.1016/j.amjcard.2018.08.042CrossRefGoogle Scholar
Norrish, G, Ding, T, Field, E, et al. Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids). JAMA Cardiol 2019; 4(9): 918927.10.1001/jamacardio.2019.2861CrossRefGoogle Scholar
Miron, A, Lafreniere-Roula, M, Steve Fan, CP, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020; 142: 217229.CrossRefGoogle ScholarPubMed